Program Information
Session Highlights for March 6 and 7
March 6, 2006
09:00-12:30 - Graduates Session
With Speakers from the DIA and National Health Authorities to discuss:
- Global DIA Activities
- Drug Development and Registration Process
- Job Opportunities in Industry & Health Authorities
- 13:30-14:30DIA Welcome and Awards CeremonyDIA Distinguished Career and
Outstanding Services Awards Ceremony
- 14:30-15:30 - Plenary Session Part 1
EU INNOVATION AND COMPETITIVENESSIntroduction by the Programme Co-Chairpersons
Iman Barilero, Johnson & Johnson PRD, UK
Marie Dray, International Regulatory Affairs Group, USA
Key Note Speakers:Georgette Lalis,European Commission,
DG Enterprise and Industry, Belgium Jean-Franois Dehecq,sanofi-aventis, France
- 16:00-17:30
Plenary Session Part 2
EU INNOVATION AND COMPETITIVENESS:
PRACTICAL IMPLICATIONS FOR AND
INVOLVEMENT OF THE STAKEHOLDERSModerators:
Iman Barilero, Johnson & Johnson PRD, UK and
Philip Brown, SCRIP, UKPanelists:
Thomas Lonngren, EMEA, EU
Martin Terberger, European Commission, Belgium
Jean Marimbert, AFSSAPS, France
Yann Le Cam, EURORDIS, France
18:00-21:00
Buffet Reception
March 7, 2006
- Late breaking news:
Addition to EuroMeeting Programme,
Tuesday, March 7
13:00-13:45
Special Session:
An Assessment of the Community System of Pharmacovigilance
Session Moderator: Marie A. Dray
Speaker: Peter Arlett, MD, European Commission, Europe
The European Commission-sponsored study An Assessment of the Community System of Pharmacovigilance was made public in February 2006 and the Commission has launched a public consultation on its results including an invitation to comment on the strengths and weaknesses of the Community System. As part of this consultation, Dr. Arlett will present the study report and attendees will be invited to make comments and pose questions on the Community System of Pharmacovigilance.
- 09:00-18:30
Poster Session/Student Poster Session
Posters selected by the review committee, addressing similar topics to those in the programme, will be on display in the exhibition area. Presenters will make themselves available to discuss their work during the coffee and lunch breaks on Tuesday at Le Palais des Congres.The poster review committee will select the three best student posters, and the winning authors will receive a EuroMeeting Student Poster Prize. The Prizes will be awarded at the student poster award ceremony on Tuesday, March 7, at 17:30 by the DIA booth in the exhibition area.
- 18:30-20:00
French Agency Satellite Meeting
THE INVOLVEMENT OF FRANCE IN THE EUROPEAN NETWORKS FOR EVALUATION AND MONITORING OF HEALTH PRODUCTSGeneral Presentation of AFSSAPS:Missions and Goals - Risk Assessment and Management
Jean Marimbert, AFSSAPS, FranceRound Table Discussion on the Common Vision on Clinical Trials in France with Representatives of LEEM, INSERM and AFSSAPS**If you are registered for the EuroMeeting, then you will have access to enter in the satellite meeting without registering separately.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
